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In recent years, the peptide drug discovery field has shown a high level of dynamism,
with hundreds of academic groups working on this topic, the creation of new peptide-focused
companies, and the consolidation of peptide business by so-called big pharma [1–4].
In the last five years (2015–2019), the U.S. Food Drug Administration (FDA) have authorized a
total of 208 new drugs (150 new chemical entities and 58 biologics) [5,6], 15 of which were peptides
or peptide-containing molecules (Table 1), which account for 7% of the total number of drugs [4,7].
This is a rather impressive number, if we consider the efforts of the pharmaceutical industry in
peptides in comparison to small molecules (in the context of this work, a peptide is defined as a
compound that contains two or more amino acids linked by an amide (peptide) bond and that can be
synthesized chemically).
The chemical structure and medical indication of the active principle ingredient of these drugs
show an excellent representation of the diversity of the peptide world.
From a chemical structure perspective, it is possible to find small peptides (Ninlar®,
Macrilen®); medium-sized peptides (Giapreza®, Scenesse®); homodetic (through amide bonds)
cyclic peptides (Vyleesi®); intra- and intermolecular disulfide-containing peptides (Parsabiv®,
containing almost exclusively D-amino acids; Trulance®); large peptides (Tymlos®, Lixisenatide®),
which in some cases are branched (Ozempic®, Tresiba®); and peptides containing radionuclides
[Lutathera®, 68Ga DOTA-TOC (68Ga-labeled 1,4,7,10-tetraazacyclododecane-N,N’,N”,N”’-tetraacetic
acid-D-Phe1-Tyr3-octreotide)]. In the case of the two antibody drug conjugates (ADC) PADCEV®
and Polivy®, the payload is the peptide monomethyl auristatin E (MMAE), a synthetic analog of the
marine natural peptide dolastatin 10. MMAE is also the drug contained in Adcetris®, which was
approved by the FDA in 2011. Of the seven FDA-approved ADCs to date, three contain a peptide.
Moreover, PADCEV® and Polivy® contain the dipeptide Val-Cit as a linker. Another peptide-based
linker, Gly-Gly-Phe-Gly, is present in the ADC Enhertu®, which was authorized by the FDA in 2019.
Oncology, with five drugs (two radio peptides and two ADCs), metabolism (three), and
endocrinology (two) are the most frequent medical indications for peptides. However, cardiovascular
conditions, gastroenterology, bone diseases, dermatology, and sexual dysfunction are also targeted
by peptides.
Of note, between 2015 and 2019, several of the new peptide-based drugs accepted by the FDA
came about from the efforts of academic groups. This highlights the importance of fostering solid and
efficient cooperation channels between academia and industry with the aim to maintain and improve
the well-being of society.
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In addition to the use of peptides as drugs or in diagnostics, these molecules are playing an
increasingly important role as drug delivery systems and as the base for new biomaterials with broad
potential applications in medicine.
Table 1. Peptide-based drugs approved by the Food Drug Administration (FDA) (2015–2019) [3–6].
Year Active Ingredient
Trade Name
Indication Features
2015 Insulin degludecTresiba® Diabetes Modified insulin with an aa deletion and a
hexadecanedioic acid via γ-Glu at the Lys (B29)
2015 IxazomibNinlar® Multiple myeloma N-Acylated, C-boronic acid dipeptide
2016 AdlyxinLixisenatide® Diabetes 44 aa GLP-1 peptide with (Lys)6 at the C-terminal
2017 AbaloparatideTymlos® Osteoporosis 34 aa analog of parathyroid hormone-related protein
2017 Angiotensin IIGiapreza® Hypotension Natural octapeptide
2017 EtelcalcetideParsabiv® Hyperparathyroidism Ac-DCys-DAla-(DArg)3-DAla-DArg-NH2 linked to
L-Cys through a disulfide bridge
2017 MacimorelinMacrilen®
Growth hormone
deficiency Pseudotripeptide N-formylated
2017 PlecanatideTrulance®
Chronic idiopathic
constipation 16 aa with two disulfides
2017 SemaglutideOzempic® Diabetes GLP-1 peptide (31 aa in the chain) with
hexadecanedioic acid via γ-Glu and mini PEG at Lys
2018 177Lu DOTA-TATELutathera®
Neuroendocrine tumors,
theranostic 177Lu chelated by DOTA bound to Tyr3-octreotate
2019 68Ga DOTA-TOC Neuroendocrine tumors,diagnostic 68Ga chelated by DOTA bound to Tyr3-octreotide
2019 AfamelanotideScenesse® Skin damage and pain 13 aa lineal peptide analog of α-MSH
2019 BremelanotideVyleesi®
Women hypoactive
sexual desire 7 aa cyclic peptide analog of α-MSH
2019 Enfortumab Vedotin-EjfvPADCEV®
Cancers expressing
Nectin-4 ADC with a synthetic analog of the marine natural
peptide dolastatin 10
2019 Polatuzumab Vedotin-PiiqPolivy®
Diffuse large B-cell
lymphoma ADC with a synthetic analog of dolastatin 10
(5-residue peptide alcohol)
This analysis supports the strength of peptides in the medicinal field. In this context, we have
decided to publish a Special Issue in Molecules, termed “Peptide Therapeutics 2.0”, which contains
excellent quality research articles and comprehensive reviews on peptides. It is hoped that some of the
peptides introduced herein will reach the market in the coming years.
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